Abstract
Objective
To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR).
Methods
Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) + golimumab (50 mg) combination therapy (n = 59) or guselkumab monotherapy (n = 32) every 4 weeks through week 20. The primary endpoint was week 24 minimal disease activity (MDA) achievement. Additional endpoints included ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70): improvements in psoriasis, dactylitis, and enthesitis; changes in patient‐reported physical function; and impact of screening C‐reactive protein (CRP) on MDA/ACR50 response.
Results
At baseline, participants had a median of 13 tender and 8 swollen joints and psoriatic body surface area of 3%; 23% had dactylitis. At week 24, 29% and 22% of participants achieved MDA with guselkumab + golimumab combination therapy and guselkumab monotherapy, respectively (odds ratio [OR] 1.4 [90% confidence interval 0.6–3.3]; P = 0.557); 44% and 22% achieved ACR50 (nominal P = 0.034). Participants with CRP levels ≥0.3mg/dL (intended enrollment population) receiving combination therapy (n = 40; monotherapy n = 22) had greater odds of achieving MDA (OR 12.3; nominal P = 0.025; 32% vs 5%) and ACR50 (OR 9.6; nominal P = 0.003; 55% vs 14%) at week 24. Combination therapy was associated with higher ACR20 (66% vs 44%) and ACR70 (27% vs 16%) responses and greater physical function improvements than monotherapy. Improvements in psoriasis, dactylitis, and enthesitis were similar across groups. No new safety signals and no tuberculosis/opportunistic infections occurred through week 36.
Conclusion
Although the primary endpoint was not achieved, secondary endpoints and exploratory analyses suggest that participants with TNFi‐IR PsA, particularly those with elevated CRP levels, could derive clinically meaningful benefits with guselkumab + golimumab combination therapy, with no new safety concerns, warranting further investigation.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, heterogeneous, inflammatory disease with varied manifestations, including peripheral arthritis, skin and nail disease, enthesitis, dactylitis, and axial involvement. 1 , 2 The burden of disease can be high, with some patients developing structural damage that irreversibly impacts physical function. 3 Patients with PsA report greater impairment of health‐related quality of life (HRQoL) than the general population. 4 Those exhibiting active disease despite treatment with conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) are commonly treated with advanced therapies, including biologic DMARDs (bDMARDs), such as tumor necrosis factor inhibitors (TNFi) and interleukin‐12/23 inhibitors (IL‐12/23i), IL‐23i, and IL‐17Ai or IL‐17A/Fi, or targeted synthetic DMARDs (eg, JAK inhibitors). Historically, TNFi have served as first‐line biologics. 5 , 6 Despite their prevalent use, >40% of patients with PsA who receive a TNFi do not meet ≥20% improvement in American College of Rheumatology response criteria (ACR20) at six months of treatment. 7 , 8 Patients treated with TNFi may also exhibit reduced efficacy with successive TNFi therapies 9 and/or decreased drug persistence with subsequent bDMARDs, even those with a different mechanism of action. 10 Furthermore, a majority of patients with PsA treated with advanced therapies fail to achieve sustained remission. 11 Thus, an unmet need remains for alternative treatment options in patients with treatment‐refractory PsA. 12
The cytokines TNF, IL‐17A, IL‐17F, and IL‐6, produced by T helper (Th17) lymphocytes and other infiltrating innate and adaptive lymphoid cells, are implicated in chronic inflammation of the skin and musculoskeletal system in patients with psoriatic disease. 13 , 14 IL‐23 is a pivotal cytokine that promotes Th17 cell differentiation and proliferation, with dysregulation of the IL‐23/Th17 axis contributing to immune‐mediated inflammation. 14 Guselkumab is a fully human, dual‐acting monoclonal antibody that binds the p19 subunit of IL‐23 and CD64 on IL‐23–producing inflammatory monocytes, thus potently neutralizing bioavailable IL‐23 at its cellular source. 15 Guselkumab is approved to treat moderate‐to‐severe plaque psoriasis, active PsA, and moderately to severely active ulcerative colitis (UC) and Crohn's disease. 16 In phase 3 studies of adults with active PsA, guselkumab significantly improved PsA signs and symptoms and inhibited radiographic progression. 17 , 18 , 19 , 20 No unexpected safety signals were observed in participants with PsA receiving guselkumab through up to two years, 21 and a favorable safety profile was reported through up to five years of guselkumab across multiple trials in participants with psoriatic disease. 22 , 23
TNF drives inflammation and activates osteoclasts and synovial fibroblasts, leading to bone destruction. 24 Golimumab, a fully human monoclonal antibody targeting TNF, is approved to treat PsA, as well as ankylosing spondylitis, juvenile (age two years and older) idiopathic arthritis, and UC. 25 In adults with active PsA, golimumab significantly reduced joint disease activity, inhibited radiographic progression, and improved associated skin and nail psoriasis, 26 , 27 while maintaining a safety profile consistent with other TNFi through up to five years. 28 , 29 , 30
Given the complex pathophysiology of PsA, targeting a single inflammatory pathway may be insufficient for adequate disease control in some patients. Combination therapy offers a promising approach by simultaneously modulating multiple immune mechanisms, thus potentially enhancing efficacy. 31 , 32 Findings from preclinical studies suggested the potential for a synergistic effect of the combination of guselkumab and golimumab on preventing systemic weight loss and local tissue inflammation in a murine colitis model. 33 The phase 2 proof‐of‐concept VEGA study (ClinicalTrials.gov ID NCT03662542) in TNFi‐naïve participants with UC demonstrated that induction therapy with guselkumab + golimumab, followed by guselkumab maintenance therapy, provided higher rates of clinical/histologic remission and endoscopic improvement and greater reduction of C‐reactive protein (CRP) levels (marker of inflammation) than either monotherapy; adverse event (AE) rates were comparable across treatment groups. 34 , 35 Although conducted in inflammatory bowel disease, these studies demonstrated an additive tissue‐level impact on inflammation, providing a rationale for combining guselkumab, an IL‐23i, with golimumab, an anti‐TNF agent, in PsA.
The phase 2a AFFINITY study (ClinicalTrials.gov ID NCT05071664, registration date: September 6, 2021) aimed to evaluate the efficacy and safety of guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with PsA and inadequate response (IR) to up to two TNFi.
PATIENTS AND METHODS
Study design
In this phase 2a, multicenter, randomized, double‐blind, active‐controlled, proof‐of‐concept study, participants were randomized 2:1 to receive guselkumab + golimumab combination therapy (subcutaneous [SC] guselkumab 100 mg and SC golimumab 50 mg) or guselkumab monotherapy (SC guselkumab 100 mg and placebo) at week 0 and then every 4 weeks (Q4W) through week 20 (Supplementary Figure S1). Treatments were provided in identical prefilled syringes with non‐identifying labels. See Supplementary methods for randomization and blinding details. The study included a screening period of up to 6 weeks; a 24‐week double‐blind, active‐controlled treatment period; and a week 36 safety follow‐up during which transition to standard‐of‐care therapy was permitted (Supplementary Figure S1). Permitted concomitant medications are detailed in Supplementary methods.
Participants
Eligible adults (≥18 to ≤65 years) had a PsA diagnosis for at least six months before initiating the study treatment and met the ClASsification criteria of Psoriatic ARthritis (CASPAR) at screening. Participants had active PsA (tender joint count [TJC] of three or more and swollen joint count [SJC] of three or more), active plaque psoriasis (at least one psoriatic plaque ≥2 cm in diameter or nail changes consistent with psoriasis), and an IR to one or two TNFi. IR was defined as lack of benefit in response to TNFi after ≥12 weeks of etanercept, adalimumab, or certolizumab pegol (or their biosimilars) or ≥14 weeks of infliximab/biosimilars. The last TNFi dose must have been administered more than five half‐lives before starting the study treatment. Participants had to be classified within at least one PsA subset (distal interphalangeal joint involvement, polyarticular arthritis without rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis). Although a high‐sensitivity CRP level of ≥0.3 mg/dL at screening was initially an inclusion requirement, a protocol amendment to mitigate the significant impact of the Ukraine/Russia conflict on study recruitment afforded no minimum CRP requirement and allowed up to 10% of participants with CRP levels <0.1 mg/dL at screening.
Participants were excluded if they had prior exposure to either guselkumab or golimumab, more than two prior TNFi (or biosimilar), or any biologic treatment other than a TNFi. See Supplementary methods for additional exclusion criteria.
Assessments
An independent joint assessor evaluated TJC (68 joints), SJC (66 joints), enthesitis using the Leeds Enthesitis Index (LEI) and Spondyloarthritis Research Consortium of Canada Index, and dactylitis with the Dactylitis Severity Score. 36 Skin disease activity was measured using percentage body surface area (BSA) with psoriasis, the Psoriasis Area and Severity Index (PASI), 36 and Investigator's Global Assessment (IGA) of psoriasis (0 = clear, 1 = minimal, 2 = mild, 3 = moderate, or 4 = severe). 37 Investigators completed the physician global assessment of disease activity using a visual analog scale (VAS; 0–10 cm). Serum samples were collected to determine CRP concentrations.
Participants reported their pain (patient pain VAS 0–10 cm), PsA disease activity (patient global assessment of disease activity [PtGA arthritis + psoriasis VAS 0–10 cm]), arthritis disease activity (PtGA arthritis VAS 0–10 cm), and impact of disease on their physical function via the 36‐item Short Form Health Survey Physical Component Summary (SF‐36 PCS) score and the Health Assessment Questionnaire Disability Index (HAQ‐DI). 36 Clinically meaningful improvements (CMIs) in SF‐36 PCS and HAQ‐DI have been defined as a 5‐point score increase and a 0.35‐point score reduction, respectively. 36 , 38
Clinical evaluation of joint response was performed using the ACR20, ACR50, and ACR70 response criteria. 36 Disease state was assessed with the minimal disease activity (MDA) criteria. 39 Reported AEs were coded using the Medical Dictionary for Regulatory Activities, version 26.0.
Endpoints
The study's prespecified primary endpoint was MDA response at week 24. Secondary efficacy endpoints included MDA response at week 16 and achievement of the following endpoints at week 24: ACR50, ACR20, and ACR70 response; resolution of enthesitis among participants with baseline enthesitis; resolution of dactylitis among participants with baseline dactylitis; PASI90 and PASI100 response (improvements of ≥90% and 100%, respectively, from baseline PASI); and IGA score of 0/1 and ≥2 grade reduction from baseline among participants with ≥3% BSA and IGA ≥2 at baseline. Changes in SF‐36 PCS and HAQ‐DI scores were also assessed through week 24.
Secondary endpoints related to safety included frequency and type of AEs and infections and rates of injection‐site reactions. AEs were summarized separately for the 24‐week treatment period and for the week 24 to 36 safety follow‐up period, during which new PsA therapies and other investigational treatments were permitted.
Statistical analyses
Assuming MDA response rates of 45% with guselkumab + golimumab combination therapy and 20% with guselkumab monotherapy at week 24, sample sizes of 60 and 30 participants, respectively, were required to provide >80% statistical power (α = 0.1; one‐sided) to detect a treatment difference in the primary endpoint.
Efficacy analyses through week 24 included all randomized participants who received at least one study treatment dose (complete or partial). The treatment effect of guselkumab + golimumab therapy versus guselkumab monotherapy was estimated using logistic regression for binary outcomes and analysis of covariance (ANCOVA) for continuous endpoints. Analyses were adjusted for treatment group, baseline csDMARD use, TJC, PASI, and patient pain. ANCOVAs also included baseline endpoint values. Estimates were reported with 90% confidence intervals (CIs). Observed participant‐level MDA component data were employed for heatmap visualizations. Responses within each heatmap were sorted independently to concentrate responders at the top; thus, a given participant does not necessarily occupy the same position across all heatmaps. Post hoc analyses using logistic regression were performed for subgroups of participants defined by screening CRP level (<0.3 vs ≥0.3 mg/dL) to assess the impact of CRP on week 24 MDA and ACR50 response, following the protocol amendment to remove the CRP level ≥0.3 mg/dL inclusion criterion.
Participants who initiated protocol‐prohibited treatment, initiated/increased csDMARD or oral corticosteroids doses, or discontinued study treatment were considered as nonresponders for binary endpoints and as having no improvement from baseline for continuous endpoints from the time of occurrence. Missing data were assumed to be missing at random and imputed conservatively as nonresponder for binary endpoints and using multiple imputation for continuous endpoints. Details of the interim analysis are provided in Supplementary methods.
Statistical comparisons were not adjusted for multiplicity testing, and all P values, except comparison of week 24 MDA response, are nominal. Statistical analyses were conducted using SAS, version 9.4.
Ethics
The trial was conducted per the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol was approved by each site's governing ethical body, and participants provided written consent.
RESULTS
Participant disposition and baseline characteristics
Between November 3, 2021, and November 28, 2023, 155 participants were screened across nine countries (Denmark, France, Hungary, Italy, Poland, Russia, Spain, Ukraine, United States), of whom 91 were randomized to treatment. Fifty‐four of 59 (92%) participants in the guselkumab + golimumab combination therapy group and 28 of 32 (88%) in the guselkumab monotherapy group completed study treatment through week 24 (Figure 1). Participants most commonly discontinued treatment due to withdrawal. Forty‐eight (81%) and 28 (88%) participants in the combination therapy and monotherapy groups, respectively, completed the week 36 safety follow‐up.
Figure 1.

Participant disposition through week 36. GOL, golimumab; GUS, guselkumab; IR, inadequate response; PsA, psoriatic arthritis; TNFi, tumor necrosis factor inhibitor.
At baseline, participants had a mean PsA duration of 7.8 (standard deviation [SD] 7.0) years, with a median TJC and SJC of 13.0 and 8.0, respectively (Table 1). Across treatment groups, 62% of participants had enthesitis and 23% had dactylitis. Skin disease activity was mild to moderate, with 38% of participants having ≥3% psoriatic BSA and an IGA score ≥2, and median psoriatic BSA and PASI scores of 3.0% and 4.8, respectively. The mean HAQ‐DI and SF‐36 PCS scores of 1.2 (SD 0.6) and 32.1 (SD 8.6), respectively, indicated moderate‐to‐severe disability and poor physical health.
Table 1.
Baseline participant demographics, clinical characteristics, and prior and concomitant treatment use*
| Guselkumab + golimumab combination therapy (N = 59) | Guselkumab monotherapy (N = 32) | Total (N = 91) | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 50.2 (10.5) | 47.7 (10.3) | 49.4 (10.5) |
| Sex, n (%) | |||
| Female | 36 (61) | 20 (62) | 56 (62) |
| Male | 23 (39) | 12 (38) | 35 (38) |
| Race, n (%) | |||
| White | 57 (97) | 32 (100) | 89 (98) |
| Not reported/unknown | 2 (3) | 0 | 2 (2) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 18 (30) | 5 (16) | 23 (25) |
| Not Hispanic or Latino | 38 (64) | 26 (81) | 64 (70) |
| Not reported/unknown | 3 (5) | 1 (3) | 4 (4) |
| Weight, kg | 86.9 (19.4) | 88.2 (23.2) | 87.4 (20.7) |
| BMI a (kg/m2) | 31.4 (6.8) | 30.5 (6.4) | 31.1 (6.6) |
| Clinical characteristics | |||
| PsA duration (years) | 8.2 (7.0) | 7.2 (7.0) | 7.8 (7.0) |
| SJC (0–66), median (range) | 7.0 (3–50) | 8.0 (3–37) | 8.0 (3–50) |
| TJC (0–68), median (range) | 13.0 (3–63) | 12.0 (3–66) | 13.0 (3–66) |
| Screening CRP (week ‐6), n (%) | |||
| <0.1 mg/dL | 6 (10) | 3 (9) | 9 (10) |
| ≥0.1 and <0.3 mg/dL | 13 (22) | 7 (22) | 20 (22) |
| ≥0.3 mg/dL | 40 (68) | 22 (69) | 62 (68) |
| Baseline CRP (week 0), n (%) | |||
| <0.1 mg/dL | 5 (8) | 8 (25) | 13 (14) |
| ≥0.1 and <0.3 mg/dL | 12 (20) | 3 (9) | 15 (16) |
| ≥0.3 mg/dL | 42 (71) | 21 (66) | 63 (69) |
| Psoriasis duration, b (years) | 13.4 (11.2) | 10.0 (8.7) | 12.2 (10.5) |
| ≥3% psoriatic BSA and IGA ≥2, n (%) | 22 (37) | 13 (41) | 35 (38) |
| Psoriatic BSA (0%–100%), median (range) | 3.0 (0–40) | 2.0 (0–51) | 3.0 (0–51) |
| PASI c (0–72), median (range) | 5.1 (0.8–29.4) | 4.0 (0.5–48.2) | 4.8 (0.5–48.2) |
| Nail involvement, d n (%) | 34 (67) | 17 (59) | 51 (64) |
| PhGA (0–10 cm VAS) | 6.4 (1.4) | 6.6 (1.7) | 6.5 (1.5) |
| Enthesitis per LEI (1–6), n (%) | 35 (59) | 21 (66) | 56 (62) |
| LEI e | 2.8 (1.7) | 2.4 (1.4) | 2.7 (1.6) |
| Enthesitis per SPARCC Index (1–16), n (%) | 46 (78) | 26 (81) | 72 (79) |
| SPARCC Index f | 5.4 (4.2) | 4.7 (3.2) | 5.2 (3.9) |
| Dactylitis per DSS (1–60), n (%) | 13 (22) | 8 (25) | 21 (23) |
| DSS g | 9.3 (12.5) | 9.6 (14.3) | 9.4 (12.9) |
| PROs | |||
| Patient pain (0–10 cm VAS) | 6.2 (1.7) | 6.5 (1.9) | 6.3 (1.7) |
| PtGA arthritis + psoriasis (0–10 cm VAS) | 6.6 (1.7) | 7.3 (1.9) | 6.9 (1.8) |
| PtGA arthritis (0–10 cm VAS) | 6.5 (1.8) | 6.9 (2.1) | 6.6 (1.9) |
| HAQ‐DI (0–3) | 1.2 (0.6) | 1.2 (0.7) | 1.2 (0.6) |
| SF‐36 PCS (US norm = 50) | 33.2 (8.5) | 30.2 (8.6) | 32.1 (8.6) |
| Prior PsA treatments | |||
| csDMARD, n (%) | 52 (88) | 32 (100) | 84 (92) |
| 1/2/≥3 DMARDs, % | 51/31/7 | 59/25/16 | 54/29/10 |
| MTX/LEF/HCQ/SSZ/other, % | 85/25/5/12/5 | 88/16/16/22/16 | 86/22/9/15/9 |
| NSAID, n (%) | 44 (75) | 24 (75) | 68 (75) |
| Systemic corticosteroids, n (%) | 18 (30) | 12 (38) | 30 (33) |
| Apremilast, n (%) | 4 (7) | 2 (6) | 6 (7) |
| TNFi, n (%) | 59 h (100) | 32 (100) | 91 (100) |
| 1 | 51 (86) | 26 (81) | 77 (85) |
| 2 | 7 (12) | 6 (19) | 13 (14) |
| Concomitant medication use at baseline | |||
| csDMARD, n (%) | 27 (46) | 14 (44) | 41 (45) |
| MTX/LEF/HCQ/SSZ, % | 31/8/3/3 | 34/3/3/3 | 32/7/3/3 |
| NSAID, n (%) | 35 (59) | 16 (50) | 51 (56) |
| Oral corticosteroids, n (%) | 5 (8) | 3 (9) | 8 (9) |
Data are mean (SD) unless otherwise noted. BMI, body mass index; BSA, body surface area; CRP, C‐reactive protein; cs, conventional synthetic; DMARD, disease‐modifying antirheumatic drug; DSS, Dactylitis Severity Score; HAQ‐DI, Health Assessment Questionnaire Disability Index; HCQ, hydroxychloroquine; IGA, Investigator's Global Assessment of psoriasis; LEF, leflunomide; LEI, Leeds Enthesitis Index; MTX, methotrexate; NSAID, nonsteroidal anti‐inflammatory drug; PASI, Psoriasis Area and Severity Index; PhGA, physician global assessment of disease activity; PRO, patient‐reported outcome; PsA, psoriatic arthritis; PtGA, patient global assessment of disease activity; SF‐36 PCS, 36‐Item Short Form Health Survey Physical Component Summary; SJC, swollen joint count; SPARCC, Spondyloarthritis Research Consortium of Canada; SSZ, sulfasalazine; TJC, tender joint count; TNFi, tumor necrosis factor inhibitor; VAS, visual analog scale.
Guselkumab + golimumab combination therapy: n = 59; guselkumab monotherapy: n = 31; total: n = 90.
Guselkumab + golimumab combination therapy: n = 57; guselkumab monotherapy: n = 32; total: n = 89.
Among participants with ≥3% psoriatic BSA and IGA ≥2 at baseline. Guselkumab + golimumab combination therapy: n = 22; guselkumab monotherapy: n = 13; total: n = 35.
Guselkumab + golimumab combination therapy: n = 51; guselkumab monotherapy: n = 29; total: n = 80.
Among participants with available assessment and LEI >0.
Among participants with available assessment and SPARCC Index >0.
Among participants with available assessment and DSS >0.
One participant in the guselkumab + golimumab combination therapy arm had three prior TNFi and was incorrectly enrolled.
Although baseline characteristics were generally balanced across treatment groups, participants receiving guselkumab + golimumab combination therapy had longer psoriasis duration (mean 13.4 vs 10.0 years) and more prevalent nail involvement (67% vs 59%) than those receiving guselkumab monotherapy (Table 1). The proportion of participants with baseline (week 0) CRP levels ≥0.3 mg/dL was higher in the combination therapy group than the monotherapy group (71% vs 66%, respectively), and fewer participants in the combination therapy group than the monotherapy group had baseline CRP levels <0.1 mg/dL (8% vs 25%). Within each treatment group, a consistent proportion of participants had CRP levels ≥0.3 mg/dL between baseline and screening (week ‐6).
Within subgroups defined by screening CRP levels, participants with CRP levels ≥0.3 mg/dL (intended enrollment population) were more likely to be female (64% vs 55%) and have dactylitis (29% vs 10%) and had higher mean body mass index (31.7 vs 29.8), longer mean PsA disease duration (8.9 vs 5.5 years), and more severe psoriasis (median PASI: 5.6 vs 2.7; ≥3% psoriatic BSA and IGA ≥2: 47% vs 21%) than those with CRP levels <0.3 mg/dL (Supplementary Table S1).
Efficacy
The primary endpoint was not met; 29% of participants receiving guselkumab + golimumab combination therapy versus 22% receiving guselkumab monotherapy achieved MDA at week 24 (odds ratio [OR] 1.4 [90% CI 0.6–3.3]; P = 0.557; Figure 2A). At week 16, 32% and 12% of participants in the combination therapy and monotherapy groups, respectively, attained this treatment target (nominal P = 0.056). Assessment of individual participant data supported group‐level findings, with a proportionally greater number of participants in the combination therapy arm than the monotherapy arm achieving the MDA criteria of TJC ≤1, SJC ≤1, HAQ‐DI ≤0.5, patient pain ≤1.5, and PtGA (arthritis + psoriasis) ≤2.0 at earlier time points and throughout week 24 (Supplementary Figure S2). Achievement of PASI ≤1, BSA ≤3%, and LEI ≤1 was more consistent across treatment groups. Post hoc analyses conducted to assess the impact of varying screening CRP levels showed a greater separation between treatment groups among participants with CRP levels ≥0.3 mg/dL versus <0.3 mg/dL at screening (two‐way interaction of treatment group with CRP level: P = 0.002), with 32% in the combination therapy group versus 5% in the monotherapy group achieving MDA at week 24 (OR 12.3 [90% CI 2.0–77.8]; nominal P = 0.025) in the high CRP level subgroup compared with 21% versus 60% (OR 0.1 [90% CI 0.0–0.6]; nominal P = 0.037) in the low CRP level subgroup (Figure 3).
Figure 2.

Proportions of participants achieving (A) MDA, (B) ACR50, (C) ACR20, and (D) ACR70 responses through week 24. *Nominal P < 0.05 versus guselkumab monotherapy. MDA was defined as the fulfillment of at least five of the following: TJC ≤1, SJC ≤1, PASI ≤1 or psoriatic BSA ≤3%, patient pain ≤1.5, PtGA arthritis + psoriasis VAS ≤2.0, HAQ‐DI score ≤0.5, and LEI ≤1. ACR20, ACR50, and ACR70 response criteria reflected the corresponding percentage improvement in TJC and SJC and in at least three of five of the following: PhGA, PtGA arthritis, patient pain, HAQ‐DI, and CRP. ACR20/50/70, ≥20%/50%/70% improvement in American College of Rheumatology response criteria; BSA, body surface area; CI, confidence interval; CRP, C‐reactive protein; GOL, golimumab; GUS, guselkumab; HAQ‐DI, Health Assessment Questionnaire Disability Index; LEI, Leeds Enthesitis Index; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; PhGA, physician global assessment of disease activity; PtGA, patient global assessment of disease activity; SJC, swollen joint count; TJC, tender joint count; VAS, visual analog scale.
Figure 3.

Impact of screening CRP levels on achievement of ACR50 and MDA at week 24. *Nominal P < 0.05; **P ≤ 0.01 versus guselkumab monotherapy. a P value for two‐way interaction of treatment group with CRP level. ACR50, ≥50% improvement in American College of Rheumatology response criteria; CI, confidence interval; CRP, C‐reactive protein; GOL, golimumab; GUS, guselkumab; MDA, minimal disease activity; n, number of participants achieving outcome; N, number of participants evaluated; OR, odds ratio.
At week 24, 44% of participants in the guselkumab + golimumab combination therapy group versus 22% in the guselkumab monotherapy group achieved ACR50 response (nominal P = 0.034; Figure 2B). The subgroup of participants with CRP levels ≥0.3 mg/dL at screening exhibited a more robust treatment difference than those with CRP levels <0.3 mg/dL at week 24 (two‐way interaction of treatment group with CRP level: P = 0.007). In the CRP level ≥0.3 mg/dL subgroup, 55% versus 14% of participants in the combination therapy and monotherapy groups, respectively, achieved ACR50 response (OR 9.6 [90% CI 2.7–33.7]; nominal P = 0.003), compared with 21% and 40%, respectively, of those with CRP levels <0.3 mg/dL (OR 0.4 [90% CI 0.1–2.0]; nominal P = 0.364; Figure 3). At week 24, 66% and 44% of participants receiving combination therapy and monotherapy, respectively, achieved ACR20 (nominal P = 0.039; Figure 2C), and 27% and 16% attained ACR70 (nominal P = 0.179; Figure 2D).
Among the 35 and 21 participants with baseline enthesitis in the guselkumab + golimumab combination therapy and guselkumab monotherapy groups, respectively, 17 (49%) and 11 (52%) achieved enthesitis resolution at week 24. Within the small subgroup of participants with baseline dactylitis, 8 of 13 (62%) in the combination therapy group and 7 of 8 (88%) in the monotherapy group achieved dactylitis resolution at week 24.
Among participants with ≥3% psoriatic BSA and IGA ≥2 at baseline, 12 of 22 (54%) receiving guselkumab + golimumab combination therapy and 5 of 13 (38%) receiving guselkumab monotherapy achieved PASI90 at week 24; 32% and 31%, respectively, attained PASI100. At week 24, 54% and 62% of participants in the combination therapy and monotherapy groups, respectively, achieved IGA 0/1 and ≥2 grade reduction from baseline.
Participants in the guselkumab + golimumab combination therapy group reported greater improvements (increased score) from baseline through week 24 in SF‐36 PCS score than those treated with guselkumab monotherapy (least squares mean [LSM] change from baseline: 8.84 vs 3.59; nominal P = 0.010), on average surpassing the SF‐36 PCS CMI threshold as early as week 8 (Figure 4A). Separation between combination therapy and monotherapy groups was noted as of week 16 (LSM change from baseline: 8.83 vs 3.93; nominal P = 0.005). Mean improvements (reduced score) in the HAQ‐DI score through week 24 among participants in the combination therapy group were −0.39 versus −0.26 with monotherapy (nominal P = 0.263; Figure 4B), with mean improvements exceeding the HAQ‐DI CMI cutoff as early as week 8 with combination therapy.
Figure 4.

LSM change from baseline in (A) SF‐36 PCS and (B) HAQ‐DI through week 24. *Nominal P < 0.05; **P ≤ 0.01 versus guselkumab monotherapy. CI, confidence interval; GOL, golimumab; GUS, guselkumab; HAQ‐DI, Health Assessment Questionnaire Disability Index; LSM, least squares mean; SF‐36 PCS, 36‐item Short Form Health Survey Physical Component Summary.
Safety
Through week 24, 66% and 56% of participants receiving guselkumab + golimumab combination therapy and guselkumab monotherapy, respectively, reported AEs (Table 2). The most common AEs (>5% of participants in either group) included diarrhea (10%), COVID‐19 (8%), and headache (8%) in the combination therapy group and nasopharyngitis (9%), upper respiratory tract infection (6%), and influenza (6%) in the monotherapy group. In the combination therapy and monotherapy groups, 4 (7%) and zero participants, respectively, had serious AEs, including one case each of COVID‐19, neuroendocrine tumor, and chronic obstructive pulmonary disease (see Adverse event narratives 1–3 in the Supplementary Material). In addition, one case of mycoplasma pneumonia was treated and resolved with no action taken concerning study treatment (see Adverse event narrative 4 in the Supplementary Material). Infections occurred in 32% and 38% of participants receiving combination therapy and monotherapy, respectively, with two cases of serious infections in the combination therapy group (one each of COVID‐19 and mycoplasma pneumonia, noted above). No case of tuberculosis or opportunistic infection was reported. Injection‐site reactions occurred in 10% and 3% of participants in the combination therapy and monotherapy groups, respectively. Two participants in the combination therapy group discontinued study treatment due to an AE: one due to malignancy (neuroendocrine tumor reported early during treatment; see Adverse event narrative 2 in the Supplementary Material) and one due to increased liver enzymes (see Adverse event narrative 5 in the Supplementary Material).
Table 2.
Summary of adverse events through the 24‐week active‐controlled treatment period*
| Guselkumab + golimumab combination (N = 59) | Guselkumab monotherapy (N = 32) | |
|---|---|---|
| Mean number of injections a | 11.2 | 10.9 |
| Participants with ≥1 | ||
| AE | 39 (66) | 18 (56) |
| AE occurring in >5% of participants in any treatment group | ||
| Back pain | 4 (7) | 0 |
| COVID‐19 | 5 (8) | 1 (3) |
| Diarrhea | 6 (10) | 0 |
| Headache | 5 (8) | 1 (3) |
| Influenza | 2 (3) | 2 (6) |
| Nasopharyngitis | 5 (8) | 3 (9) |
| Nausea | 3 (5) | 0 |
| Oral candidiasis | 0 | 2 (6) |
| Psoriatic arthropathy | 3 (5) | 0 |
| Upper respiratory tract infection | 3 (5) | 2 (6) |
| Urinary tract infection | 0 | 2 (6) |
| Serious AE b | 4 (7) | 0 |
| AE leading to discontinuation c | 2 (3) | 0 |
| Infection | 19 (32) | 12 (38) |
| Serious infection | 2 (3) | 0 |
| Opportunistic infection | 0 | 0 |
| Active TB | 0 | 0 |
| Injection‐site reaction d | 6 (10) | 1 (3) |
| AE leading to death | 0 | 0 |
Data are n (%) unless otherwise noted. AE, adverse event; SC, subcutaneous; TB, tuberculosis.
Sum of guselkumab, placebo, or golimumab injections received.
Serious AEs through week 24 include malignancy (neuroendocrine tumor), chronic obstructive pulmonary disease, COVID‐19, and mycoplasma pneumonia.
AEs leading to discontinuation through week 24 include malignancy (neuroendocrine tumor) and increased liver transaminases.
Injection‐site reaction was defined as any adverse reaction at an SC study treatment injection site.
From week 24 to the week 36 safety follow‐up, no deaths, serious AEs, serious infections, tuberculosis, or opportunistic infections occurred. Three additional participants in the guselkumab + golimumab combination therapy group reported AEs (42/59 [71.2%]). One additional case of infection occurred in the guselkumab monotherapy group (13/32 [40.6%]).
DISCUSSION
AFFINITY, a phase 2a proof‐of‐concept study, evaluated the efficacy and safety of dual blockade of IL‐23 with guselkumab and TNF with golimumab compared with guselkumab monotherapy in participants with active PsA and TNFi‐IR. Although the primary endpoint was not met, guselkumab + golimumab combination therapy demonstrated numerically higher rates of MDA response than guselkumab monotherapy at week 24. A higher MDA response rate was observed in the combination therapy group than the monotherapy group at week 16. Higher rates of improved joint‐related signs and symptoms of PsA (ie, ACR20/50/70) were seen among participants receiving combination therapy versus monotherapy through week 24. Participant‐level data supported group‐level findings, as proportionally more participants receiving combination therapy than monotherapy achieved stringent disease targets more rapidly, indicating minimal joint disease and participant‐reported pain, global disease activity, and impairment of physical function. Additionally, participant achievement of minimal skin disease and enthesitis was more consistent across treatment arms, potentially contributing to a lack of significant difference in MDA achievement between study groups.
Post hoc analyses assessing the impact of CRP levels at screening showed that in the intended enrollment population of participants with TNFi‐IR PsA and CRP levels ≥0.3 mg/dL, those receiving combination therapy had significantly greater odds of achieving MDA as well as ACR50 at week 24. These findings suggest that participants with a higher systemic inflammatory burden may derive a greater benefit from the additive effect of guselkumab + golimumab than those with more modest systemic inflammation. This possibility, along with the potential impact of other markers of inflammation, should be tested in further studies, ideally among a larger cohort of individuals with active PsA.
Participants receiving guselkumab + golimumab combination therapy also reported improved physical aspects of HRQoL and daily function, further supporting the benefit of this combination therapy on joint disease. As early as week 8, a greater improvement was apparent in SF‐36 PCS and HAQ‐DI scores with combination therapy than monotherapy, with SF‐36 PCS scores continuing to improve through week 24. These findings, along with week 16 MDA achievement rates, suggest that the combined effect of guselkumab + golimumab may confer a more rapid onset of response, although larger studies are needed to verify this trend.
Skin responses and resolution of enthesitis and dactylitis were consistent with the known effects of guselkumab, 19 with no incremental benefit from the addition of a TNFi. However, low numbers of participants with more extensive psoriatic involvement (≥3% psoriatic BSA and IGA ≥2) or baseline dactylitis limit data interpretation. Additionally, lower initial skin disease burden may make it harder to distinguish improvement in measures of psoriasis, potentially obscuring modest treatment responses. Previous reports have shown that PASI utility in particular is impacted by baseline severity of psoriasis. 40 , 41
Although AFFINITY was not sufficiently powered across examined joint efficacy endpoints, clinical responses in measures of joint disease and patient‐reported outcomes in the guselkumab monotherapy group were consistent with those observed in a phase 3 study evaluating a limited number of participants with active PsA and TNFi‐IR receiving a guselkumab Q8W regimen. 19 More recently, efficacy of guselkumab Q4W and Q8W regimens in adults with active PsA and TNFi‐IR was prospectively investigated in the well‐powered, double‐blind, randomized, placebo‐controlled phase 3 SOLSTICE study (ClinicalTrials.gov ID NCT04936308). 42 , 43 , 44 Findings through week 24 of SOLSTICE showed significantly greater achievement of joint improvement, skin clearance, and MDA with both guselkumab regimens versus placebo and meaningful improvements in physical function, fatigue, and HRQoL. 42
Both participant‐ and group‐level findings suggested that the combination of guselkumab + golimumab may have a greater impact on joint disease than psoriasis and enthesitis. IL‐23 is a major cytokine contributing to inflammation in the skin and entheses, 45 , 46 whereas joint disease activity involves additional mechanisms of pathogenesis. Thus, neutralizing both TNF and IL‐23 may have a more marked effect on joints, with guselkumab's role in modulating IL‐23–dependent proinflammatory cytokines complementing golimumab's effects on reducing TNF‐induced synovial inflammation and altered bone remodeling. 24 , 46 Ongoing biomarker analyses may offer insights into the pathways affected by combination therapy and help characterize underlying tissue‐specific responses.
AEs through week 24 were reported for 66% and 56% of participants receiving guselkumab + golimumab combination therapy and guselkumab monotherapy, respectively. Rates of infections were comparable in the combination therapy and monotherapy groups, and no opportunistic infections were reported. The only serious AE considered by the investigator as related to study treatment (mycoplasma pneumonia in the combination therapy group) resolved with treatment, with no impact on study treatment/participation. Overall, no new or unexpected safety findings, relative to the accumulated safety profiles of guselkumab and golimumab previously established in patients with PsA, 22 , 23 , 28 , 29 , 30 were identified in the combination therapy group through week 36.
The potential synergy of guselkumab, an IL‐23i, and golimumab, an anti‐TNF agent, in simultaneously blocking multiple inflammatory pathways may give rise to a novel mechanism of action with superior disease control than either agent alone, without new safety concerns. Transcriptional profiling of colon biopsy samples obtained from VEGA study participants with UC 34 showed significant reductions in major inflammatory modules with combination therapy as early as week 4 that persisted through week 38 of guselkumab maintenance therapy. 47 Correlative analyses indicated a role for guselkumab as a primary driver of tissue healing, with golimumab contributing to anti‐innate inflammatory activity. The complementary and differential activities of guselkumab and golimumab may extend to the findings of the present study in PsA and possibly other chronic inflammatory diseases. Despite prior reports of limited efficacy and safety concerns with bDMARD combination therapy in rheumatoid arthritis (RA) 48 and no clear evidence that IL‐17/TNF inhibition with the bispecific antibody ABT‐122 provides benefit beyond TNFi in RA or PsA, 49 , 50 current findings in patients with TNFi‐IR PsA indicate that the combination of an IL‐23i with a TNFi may offer a new treatment approach to raise the therapeutic ceiling in some patients with PsA. Interestingly, the new definition of difficult‐to‐treat PsA proposed by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) specifies refractory disease with persistent inflammation despite multiple treatments. 51 Because AFFINITY was conducted in a population with TNFi‐IR and considering that participants with objective evidence of elevated inflammatory activity were more likely to respond to guselkumab + golimumab combination therapy than guselkumab monotherapy, this treatment strategy may offer a foundation for optimal care in the growing population of patients with refractory PsA in the setting of persistent inflammation. The ongoing phase 2b randomized, double‐blind, placebo‐controlled trials in participants with moderately to severely active UC (DUET‐UC, ClinicalTrials.gov ID NCT05242484) and Crohn's disease (DUET‐CD, ClinicalTrials.gov ID NCT05242471), which is investigating guselkumab + golimumab combination therapy compared with either agent alone, will provide additional efficacy and safety data for this treatment in participants with refractory inflammatory bowel disease, a known associated condition of PsA.
AFFINITY used validated clinical PsA and patient‐reported measures and employed nonresponder imputation as a stringent method for estimating treatment effect and multiple imputation to reduce bias. Given the proof‐of‐concept nature of AFFINITY, the trial sample size was relatively small, which may limit the generalizability of the findings and may have reduced the statistical power to detect differences in secondary endpoints. As evidenced by post hoc analyses, the protocol amendment to remove minimal CRP requirements likely impacted study findings. Although the trial was adequately powered to assess the primary endpoint, fewer participants with intended characteristics were enrolled, further limiting analyses for the planned study population sample. Only a subset of the trial population had psoriasis, enthesitis, and dactylitis involvement, and thus treatment responses in these outcome measures should be interpreted with caution. Because combination therapy may provide added benefits in joint efficacy in a setting of a higher inflammatory burden, future study design considerations may include incorporation of ACR50 as the primary endpoint, assessment of both monotherapy arms, and evaluation of response in a broader range of patients with PsA, regardless of prior treatment.
In conclusion, among participants with active PsA and nonresponse or loss of response to a TNFi, the combination of the IL‐23i guselkumab and the TNFi golimumab may confer clinically meaningful benefits in joint disease activity and physical function over guselkumab monotherapy, with no new safety findings as compared with the established profiles of either drug, warranting further investigation. Greater impact of combination therapy was seen among participants with higher levels of systemic inflammation at screening, which is known to drive joint disease activity and structural damage, suggesting that future studies should focus on this patient population.
AUTHOR CONTRIBUTIONS
All authors contributed to at least one of the following manuscript preparation roles: conceptualization AND/OR methodology, software, investigation, formal analysis, data curation, visualization, and validation AND drafting or reviewing/editing the final draft. As corresponding author, Dr Scher confirms that all authors have provided the final approval of the version to be published and takes responsibility for the affirmations regarding article submission (eg, not under consideration by another journal), the integrity of the data presented, and the statements regarding compliance with institutional review board/Declaration of Helsinki requirements.
ROLE OF THE STUDY SPONSOR
Authors employed by Johnson & Johnson were involved in the study design and the collection, analysis, or interpretation of the data or the decision to submit the manuscript for publication. The authors thank Danielle Murphy, Karissa Lozenski, Michelle Perate, Soumya Chakravarty, Bryan Boone, and Aaron Hinken (all of Johnson & Johnson) for substantive manuscript review. Medical writing support was provided by Joanna Dembowy, PhD, of JSS Medical Research Inc, under the direction of the authors and in accordance with Good Publication Practice guidelines (Ann Intern Med 2022;175 (9):1298–1304). Publication of this article was contingent upon approval by Johnson & Johnson.
Supporting information
Disclosure Form:
Data S1. Supporting Information.
ClinicalTrials.gov identifier: NCT05071664.
Supported by Johnson & Johnson.
1Division of Rheumatology, Psoriatic Arthritis Center and Colton Center for Autoimmunity, New York University Grossman School of Medicine, New York, New York; 2College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom; 3Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; 4Department of Dermatology and Division of Rheumatology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas; 5University of New South Wales, Randwick, New South Wales, Australia; 6Division of Rheumatology, Department of Medicine and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; 7Institute of Medical Science, Toronto, Ontario, Canada; 8Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; 9Johnson & Johnson, Spring House, Pennsylvania; 10University of California, San Francisco; 11Rheumatology Research, Providence Swedish Medical Center, Seattle, Washington; 12University of Washington School of Medicine, Seattle; 13University of Rochester Medical Center, Rochester, New York.
The data‐sharing policy of Johnson & Johnson is available at https://innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.
Additional supplementary information cited in this article can be found online in the Supporting Information section (https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70152).
Author disclosures are available at https://onlinelibrary.wiley.com/doi/10.1002/art.70152.
References
- 1. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist‐diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013;69(5):729–735. doi: 10.1016/j.jaad.2013.07.023 [DOI] [PubMed] [Google Scholar]
- 2. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017;376(21):2095–2096. [DOI] [PubMed] [Google Scholar]
- 3. Kerschbaumer A, Baker D, Smolen JS, et al. The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis 2017;76(12):2038–2044. doi: 10.1136/annrheumdis-2017-211433 [DOI] [PubMed] [Google Scholar]
- 4. James L, Hailey LH, Suribhatla R, et al. The impact of psoriatic arthritis on quality of life: a systematic review. Ther Adv Musculoskelet Dis 2024;16:1759720X241295920. doi: 10.1177/1759720X241295920 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Coates LC, Soriano ER, Corp N, et al; GRAPPA Treatment Recommendations domain subcommittees . Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022;18(8):465–479. doi: 10.1038/s41584-022-00798-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79(6):700–712. doi: 10.1136/annrheumdis-2020-217159 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Mease P. A short history of biological therapy for psoriatic arthritis. Clin Exp Rheumatol 2015;33(5 suppl 93):S104–S108. [PubMed] [Google Scholar]
- 8. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38(6):727–735. [DOI] [PubMed] [Google Scholar]
- 9. Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum 2017;47(1):29–37. doi: 10.1016/j.semarthrit.2017.02.001 [DOI] [PubMed] [Google Scholar]
- 10. Harrold LR, Stolshek BS, Rebello S, et al. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Clin Rheumatol 2017;36(4):895–901. doi: 10.1007/s10067-017-3593-x [DOI] [PubMed] [Google Scholar]
- 11. Gladman DD, Chandran V, Rosen CF, et al. Residual disease activity in Canadian patients with psoriatic arthritis treated with advanced therapies: results from a multiregistry analysis (UNISON‐PsA). J Rheumatol 2024;51(5):479–487. doi: 10.3899/jrheum.2023-0716 [DOI] [PubMed] [Google Scholar]
- 12. Ribeiro AL, Singla S, Chandran V, et al. Deciphering difficult‐to‐treat psoriatic arthritis (D2T‐PsA): a GRAPPA perspective from an international survey of healthcare professionals. Rheumatol Adv Pract 2024;8(3):rkae074. doi: 10.1093/rap/rkae074 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 2020;323(19):1945–1960. doi: 10.1001/jama.2020.4006 [DOI] [PubMed] [Google Scholar]
- 14. Schinocca C, Rizzo C, Fasano S, et al. Role of the IL‐23/IL‐17 pathway in rheumatic diseases: an overview. Front Immunol 2021;12:637829. doi: 10.3389/fimmu.2021.637829 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Sachen KL, Hammaker D, Sarabia I, et al. Guselkumab binding to CD64+ IL‐23‐producing myeloid cells enhances potency for neutralizing IL‐23 signaling. Front Immunol 2025;16:1532852. doi: 10.3389/fimmu.2025.1532852 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Tremfya: package insert. Janssen Biotech, Inc; 2025. [Google Scholar]
- 17. Mease PJ, Rahman P, Gottlieb AB, et al; DISCOVER‐2 Study Group . Guselkumab in biologic‐naive patients with active psoriatic arthritis (DISCOVER‐2): a double‐blind, randomised, placebo‐controlled phase 3 trial. Lancet 2020;395(10230):1126–1136. doi: 10.1016/S0140-6736(20)30263-4 [DOI] [PubMed] [Google Scholar]
- 18. Deodhar A, Helliwell PS, Boehncke WH, et al; DISCOVER‐1 Study Group . Guselkumab in patients with active psoriatic arthritis who were biologic‐naive or had previously received TNFα inhibitor treatment (DISCOVER‐1): a double‐blind, randomised, placebo‐controlled phase 3 trial. Lancet 2020;395(10230):1115–1125. doi: 10.1016/S0140-6736(20)30265-8 [DOI] [PubMed] [Google Scholar]
- 19. Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis 2022;81(3):359–369. doi: 10.1136/annrheumdis-2021-220991 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with the selective interleukin‐23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double‐blind, placebo‐controlled APEX study. Ann Rheum Dis 2025;84(12):1983–1994. doi: 10.1016/j.ard.2025.08.006 [DOI] [PubMed] [Google Scholar]
- 21. McInnes IB, Rahman P, Gottlieb AB, et al. Long‐term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin‐23, through 2 years: results from a phase 3, randomized, double‐blind, placebo‐controlled study conducted in biologic‐naive patients with active psoriatic arthritis. Arthritis Rheumatol 2022;74(3):475–485. doi: 10.1002/art.42010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Lebwohl MG, Merola JF, Rowland K, et al. Safety of guselkumab treatment for up to 5 years in patients with moderate‐to‐severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient‐years of exposure. Br J Dermatol 2023;189(1):42–52. doi: 10.1093/bjd/ljad115 [DOI] [PubMed] [Google Scholar]
- 23. Strober B, Coates LC, Lebwohl MG, et al. Long‐term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf 2024;47(1):39–57. doi: 10.1007/s40264-023-01361-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF‐α) in autoimmune disease and current TNF‐alpha inhibitors in therapeutics. Int J Mol Sci 2021;22(5):2719. doi: 10.3390/ijms22052719 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Simponi: package insert. Janssen Biotech, Inc; 2025. [Google Scholar]
- 26. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty‐four‐week efficacy and safety results of a randomized, placebo‐controlled study. Arthritis Rheum 2009;60(4):976–986. doi: 10.1002/art.24403 [DOI] [PubMed] [Google Scholar]
- 27. Kavanaugh A, Husni ME, Harrison DD, et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty‐four of the GO‐VIBRANT study. Arthritis Rheumatol 2017;69(11):2151–2161. doi: 10.1002/art.40226 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long‐term extension of a randomised, placebo‐controlled trial (the GO‐REVEAL study). Ann Rheum Dis 2014;73(9):1689–1694. doi: 10.1136/annrheumdis-2013-204902 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Husni ME, Deodhar A, Schwartzman S, et al. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Res Ther 2022;24(1):73. doi: 10.1186/s13075-022-02753-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Kay J, Fleischmann R, Keystone E, et al. Five‐year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2016;43(12):2120–2130. doi: 10.3899/jrheum.160420 [DOI] [PubMed] [Google Scholar]
- 31. Cuchacovich R, Garcia‐Valladares I, Espinoza LR. Combination biologic treatment of refractory psoriasis and psoriatic arthritis. J Rheumatol 2012;39(1):187–193. doi: 10.3899/jrheum.110295 [DOI] [PubMed] [Google Scholar]
- 32. Scher JU, Ogdie A, Merola JF, et al. Moving the goalpost toward remission: the case for combination immunomodulatory therapies in psoriatic arthritis. Arthritis Rheumatol 2021;73(9):1574–1578. doi: 10.1002/art.41765 [DOI] [PubMed] [Google Scholar]
- 33. Perrigoue J, Muniz‐Bongers L, Ong L, et al. In silico evaluation and pre‐clinical efficacy of anti‐TNF and anti‐IL‐23 combination therapy in inflammatory bowel disease. J Crohns Colitis 2022;16(suppl 1):i348. doi: 10.1093/ecco-jcc/jjab232.455 [DOI] [Google Scholar]
- 34. Feagan BG, Sands BE, Sandborn WJ, et al; VEGA Study Group . Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double‐blind, controlled, phase 2, proof‐of‐concept trial. Lancet Gastroenterol Hepatol 2023;8(4):307–320. doi: 10.1016/S2468-1253(22)00427-7 [DOI] [PubMed] [Google Scholar]
- 35. Shao J, Vetter M, Vermeulen A, et al. Combination therapy with guselkumab and golimumab in patients with moderately to severely active ulcerative colitis: pharmacokinetics, immunogenicity and drug‐drug interactions. Clin Pharmacol Ther 2024;115(6):1418–1427. doi: 10.1002/cpt.3235 [DOI] [PubMed] [Google Scholar]
- 36. Ogdie A, Coates LC, Mease P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res (Hoboken) 2020;72(suppl 10):82–109. doi: 10.1002/acr.24242 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Langley RG, Feldman SR, Nyirady J, et al. The 5‐point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2015;26(1):23–31. doi: 10.3109/09546634.2013.865009 [DOI] [PubMed] [Google Scholar]
- 38. Ware JE Jr, Sherbourne CD. The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Med Care 1992;30(6):473–483. doi: 10.1097/00005650-199206000-00002 [DOI] [PubMed] [Google Scholar]
- 39. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010;62(7):965–969. doi: 10.1002/acr.20155 [DOI] [PubMed] [Google Scholar]
- 40. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50(6):859–866. [DOI] [PubMed] [Google Scholar]
- 41. Mahil SK, Wilson N, Dand N, et al; BADBIR study group and the PSORT consortium . Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol 2020;182(5):1158–1166. doi: 10.1111/bjd.18333 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Ogdie A, Merola JF, Mease PJ, et al. Efficacy and safety of guselkumab in participants with active psoriatic arthritis after inadequate response to one prior tumor necrosis factor inhibitor: week‐24 results of the phase 3, randomized, placebo‐controlled study. Arthritis Rheumatol 2026;78(8):1674–1686. doi: 10.1002/art.70092 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Ogdie A, Merola JF, Mease PJ, et al. Efficacy and safety of guselkumab in participants with active psoriatic arthritis and inadequate response/intolerance to one prior tumor necrosis factor inhibitor. Abstract presented at: Congress of Clinical Rheumatology – West; September 18–21, 2025; Huntington Beach, CA.
- 44. Gottlieb AB, Merola JF, Mease PJ, et al. Improvements in patient reported outcomes through 24 weeks of guselkumab treatment in participants with active psoriatic arthritis and inadequate response/intolerance to one prior TNF inhibitor. Abstract presented at: Congress of Clinical Rheumatology – West; September 18–21, 2025; Huntington Beach, CA.
- 45. Bridgewood C, Sharif K, Sherlock J, et al. Interleukin‐23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy. Immunol Rev 2020;294(1):27–47. doi: 10.1111/imr.12840 [DOI] [PubMed] [Google Scholar]
- 46. Krueger JG, Eyerich K, Kuchroo VK, et al. IL‐23 past, present, and future: a roadmap to advancing IL‐23 science and therapy. Front Immunol 2024;15:1331217. doi: 10.3389/fimmu.2024.1331217 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Richards D, Vetter M, Germinaro M, et al. Guselkumab and golimumab combination induction therapy in ulcerative colitis results in early local tissue healing that is sustained through guselkumab maintenance therapy [abstract]. J Crohns Colitis 2024;18(suppl 1):i170–i171. doi: 10.1093/ecco-jcc/jjad212.0094 [DOI] [Google Scholar]
- 48. Boleto G, Kanagaratnam L, Dramé M, et al. Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: A systematic review and meta‐analysis. Semin Arthritis Rheum 2019;49(1):35–42. doi: 10.1016/j.semarthrit.2018.12.003 [DOI] [PubMed] [Google Scholar]
- 49. Genovese MC, Weinblatt ME, Mease PJ, et al. Dual inhibition of tumour necrosis factor and interleukin‐17A with ABT‐122: open‐label long‐term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology (Oxford) 2018;57(11):1972–1981. doi: 10.1093/rheumatology/key173 [DOI] [PubMed] [Google Scholar]
- 50. Khatri A, Klünder B, Peloso PM, et al. Exposure‐response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT‐122 in rheumatoid or psoriatic arthritis. Rheumatology (Oxford) 2019;58(2):352–360. doi: 10.1093/rheumatology/key312 [DOI] [PubMed] [Google Scholar]
- 51. Ribeiro AL, Singla S, Hay‐Rollins C, et al. Deciphering difficult‐to‐treat psoriatic arthritis: insights from an international survey of patients with psoriatic arthritis. Rheumatology (Oxford) 2025;64(8):4641–4649. doi: 10.1093/rheumatology/keaf207 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Disclosure Form:
Data S1. Supporting Information.
